QuidelOrtho Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Brian Blaser

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	4.3yrs

Recente managementupdates

Recent updates

QuidelOrtho: Highly Levered With Questionable Growth

Nov 26

Lacklustre Performance Is Driving QuidelOrtho Corporation's (NASDAQ:QDEL) Low P/S

Nov 17

QuidelOrtho (NASDAQ:QDEL) Seems To Be Using A Lot Of Debt

Sep 15

QuidelOrtho Corporation (NASDAQ:QDEL) Stock Catapults 38% Though Its Price And Business Still Lag The Industry

Aug 09

QuidelOrtho: Attractive Valuation Despite Weak Performance

Apr 13

We Think QuidelOrtho (NASDAQ:QDEL) Is Taking Some Risk With Its Debt

Apr 08

QuidelOrtho Corporation's (NASDAQ:QDEL) 38% Dip In Price Shows Sentiment Is Matching Revenues

Feb 15

QuidelOrtho Corporation (NASDAQ:QDEL) Shares Could Be 38% Below Their Intrinsic Value Estimate

Mar 13

QuidelOrtho Corporation Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Feb 18

An Intrinsic Calculation For QuidelOrtho Corporation (NASDAQ:QDEL) Suggests It's 47% Undervalued

Nov 25

QuidelOrtho forecasts strong Q3 revenue above estimates, shares rise ~6% after hours

Oct 12

CEO

Brian Blaser (59 yo)

less than a year

Tenure

Mr. Brian J. Blaser serves as CEO & President at QuidelOrtho Corporation since May 06, 2024 & serves as it's Director since May 15, 2024. He served as an Independent Director at Quanterix Corporation since...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Joseph Busky	Chief Financial Officer	2.5yrs	US$2.94m	0.018% $ 478.9k
Werner Kroll	Executive Officer	10.5yrs	US$2.03m	0.054% $ 1.5m
Brian Blaser	President	less than a year	geen gegevens	geen gegevens
Philip McLellan	Chief Operations Officer	no data	geen gegevens	0.0083% $ 222.7k
Jonathan Siegrist	Executive VP of Research & Development and CTO	less than a year	geen gegevens	geen gegevens
Juliet Cunningham	Vice President of Investor Relations	1.2yrs	geen gegevens	geen gegevens
Michelle Hodges	Chief Legal Officer	3.9yrs	US$3.55m	0.025% $ 662.8k
Ronald Bowman	Chief Human Resources Officer	less than a year	geen gegevens	geen gegevens
William Ferenczy	Point of Care Business Unit Leader	no data	geen gegevens	geen gegevens
Tamara Ranalli	Molecular Diagnostics Business Unit Leader	no data	geen gegevens	geen gegevens

0.8yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van QDEL wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Brian Blaser	President	less than a year	geen gegevens	geen gegevens
Ann Rhoads	Independent Director	4.3yrs	US$314.47k	0.012% $ 326.4k
Kenneth Widder	Independent Director	10yrs	US$320.47k	0.042% $ 1.1m
Kenneth Buechler	Independent Non-Executive Chairman	17yrs	US$411.50k	0.13% $ 3.5m
Edward Michael	Independent Director	5.9yrs	US$326.94k	0.023% $ 630.4k
Mary Polan	Independent Director	31.8yrs	US$300.95k	0.035% $ 943.5k
Evelyn Dilsaver	Independent Director	2.5yrs	US$286.95k	0.0077% $ 209.2k
Matthew Strobeck	Independent Director	6.6yrs	US$280.00k	0.044% $ 1.2m
Robert Schmidt	Independent Director	2.5yrs	US$70.00k	geen gegevens
Joseph Wilkins	Independent Director	3.8yrs	US$280.00k	0.0098% $ 264.0k
James Prutow	Independent Director	less than a year	US$110.83k	0.0023% $ 61.0k

4.3yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van QDEL wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

QuidelOrtho Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Quidelortho Corporation Announces Executive Changes

QuidelOrtho Corporation Appoints Jonathan Siegrist, PhD, as New Executive Vice President of Research and Development and Chief Technology Officer

QuidelOrtho Corporation Appoints Lee Bowman as Chief Human Resources Officer

QuidelOrtho Corporation Announces CEO Changes

QuidelOrtho Corporation Announces CEO Changes

President exercised options and sold US$509k worth of stock

Recent updates

QuidelOrtho: Highly Levered With Questionable Growth

QuidelOrtho Corporation has completed a Follow-on Equity Offering in the amount of $294.062515 million.

QuidelOrtho Corporation has filed a Follow-on Equity Offering.

Lacklustre Performance Is Driving QuidelOrtho Corporation's (NASDAQ:QDEL) Low P/S

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Quidelortho Corporation Announces Executive Changes

QuidelOrtho Corporation to Report Q3, 2024 Results on Nov 07, 2024

Consensus EPS estimates fall by 42%

QuidelOrtho Corporation Appoints Jonathan Siegrist, PhD, as New Executive Vice President of Research and Development and Chief Technology Officer

Price target increased by 7.3% to US$53.00

QuidelOrtho (NASDAQ:QDEL) Seems To Be Using A Lot Of Debt

QuidelOrtho Corporation Appoints Lee Bowman as Chief Human Resources Officer

QuidelOrtho Corporation (NASDAQ:QDEL) Stock Catapults 38% Though Its Price And Business Still Lag The Industry

QuidelOrtho Corporation(NasdaqGS:QDEL) dropped from S&P 400

QuidelOrtho Corporation to Report Q2, 2024 Results on Jul 31, 2024

QuidelOrtho Corporation Suspends Earnings Guidance for the Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

QuidelOrtho Corporation Announces CEO Changes

New major risk - Revenue and earnings growth

QuidelOrtho Corporation to Report Q1, 2024 Results on May 08, 2024

Labaton Keller Sucharow LLP Announces Securities Class Action Lawsuit Filed Against QuidelOrtho Corporation and Certain Executives

QuidelOrtho: Attractive Valuation Despite Weak Performance

Labaton Keller Sucharow LLP Announces Securities Class Action Lawsuit Filed Against QuidelOrtho Corporation and Certain Executives

We Think QuidelOrtho (NASDAQ:QDEL) Is Taking Some Risk With Its Debt

Consensus EPS estimates fall by 89%

Price target decreased by 7.0% to US$56.40

QuidelOrtho Corporation Receives FDA 510(K) Clearance for its QuickVue COVID-19 Test

Consensus EPS estimates fall by 602%

QuidelOrtho Corporation Announces CEO Changes

Consensus EPS estimates have been downgraded.

QuidelOrtho Corporation's (NASDAQ:QDEL) 38% Dip In Price Shows Sentiment Is Matching Revenues

New minor risk - Share price stability

Full year 2023 earnings: EPS and revenues miss analyst expectations

QuidelOrtho Corporation Provides Earnings Guidance for the Fiscal Year 2024

President exercised options and sold US$509k worth of stock

QuidelOrtho Corporation to Report Q4, 2023 Results on Feb 13, 2024

QuidelOrtho Corporation Provides Revenue Guidance for the Year 2023

QuidelOrtho Corporation Receives 510(K) Clearance for Savanna(R) Multiplex Molecular Platform and Savanna(R) HSV 1+2/VZV PCR Assay

Price target decreased by 7.8% to US$101

QuidelOrtho Corporation Announces Board Changes

Price target decreased by 9.5% to US$110

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

QuidelOrtho Corporation Provides Earnings Guidance for the Year 2023

QuidelOrtho Corporation to Report Q3, 2023 Results on Nov 01, 2023

QuidelOrtho Corporation Receives CLIA Waiver for Sofia 2 SARS Antigen+ FIA

QuidelOrtho Corporation Announces Resignation of Christopher M. Smith from the Board, Effective August 31, 2023

Consensus EPS estimates fall by 31%

QuidelOrtho Corporation Revises Earnings Guidance for the Year 2023

New major risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

QuidelOrtho Corporation to Report Q2, 2023 Results on Aug 08, 2023

Consensus EPS estimates fall by 12%, revenue upgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

QuidelOrtho Corporation Revises Earnings Guidance for the Year 2023

QuidelOrtho Corporation (NASDAQ:QDEL) Shares Could Be 38% Below Their Intrinsic Value Estimate

Independent Non-Executive Chairman exercised options and sold US$538k worth of stock

QuidelOrtho Corporation Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

President exercised options and sold US$393k worth of stock

QuidelOrtho Corporation Provides Financial Guidance for the Fiscal Year 2023

President exercised options and sold US$341k worth of stock

Consensus forecasts updated

QuidelOrtho Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year Ended January 1, 2023

QuidelOrtho Corporation Announces Health Canada Grants License for Quidel TriageTrue High-Sensitivity Troponin I Test to Aid in the Diagnosis of Myocardial Infarction

Investor sentiment deteriorated over the past week

QuidelOrtho Corporation Announces Executive Changes

An Intrinsic Calculation For QuidelOrtho Corporation (NASDAQ:QDEL) Suggests It's 47% Undervalued

General Counsel exercised options and sold US$173k worth of stock

High number of new directors

General Counsel exercised options and sold US$173k worth of stock